These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 7625674)
41. Factors influencing antibody responses to acellular pertussis vaccines. Trollfors B Dev Biol Stand; 1997; 89():279-82. PubMed ID: 9272361 [TBL] [Abstract][Full Text] [Related]
42. Antibody level of New Zealand children immunized with the triple vaccine DTP (diphtheria-tetanus-pertussis). Lau RC Epidemiol Infect; 1988 Oct; 101(2):405-10. PubMed ID: 2903065 [TBL] [Abstract][Full Text] [Related]
43. Immunogenicity of a Haemophilus influenzae type b vaccine in combination with diphtheria-pertussis-tetanus vaccine in infants. Coulehan JL; Hallowell C; Michaels RH; Welty TK; Lui N; Kuo JS J Infect Dis; 1983 Sep; 148(3):530-4. PubMed ID: 6311913 [TBL] [Abstract][Full Text] [Related]
44. Progress and challenges for a new combination vaccine composed of diphtheria, tetanus, acellular pertussis, and Haemophilus b conjugate. Madore DV Ann N Y Acad Sci; 1995 May; 754():356-8. PubMed ID: 7625673 [No Abstract] [Full Text] [Related]
45. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. Ausiello CM; Lande R; Urbani F; Di Carlo B; Stefanelli P; Salmaso S; Mastrantonio P; Cassone A J Infect Dis; 2000 Jun; 181(6):1989-95. PubMed ID: 10837180 [TBL] [Abstract][Full Text] [Related]
46. Comparative biological activities of acellular pertussis vaccines produced by Kitasato. Watanabe M; Izumiya K; Sato T; Yoshino K; Nakagawa N; Ohoishi M; Hoshino M Kitasato Arch Exp Med; 1991 Apr; 64(1):31-42. PubMed ID: 1798236 [TBL] [Abstract][Full Text] [Related]
47. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses. Halperin SA; King J; Law B; Mills E; Willems P Clin Infect Dis; 1999 May; 28(5):995-1001. PubMed ID: 10452624 [TBL] [Abstract][Full Text] [Related]
48. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526 [TBL] [Abstract][Full Text] [Related]
50. Diphtheria and tetanus toxoids and pertussis vaccine adsorbed (DTP): response to varying immunizing dosage and schedule. Barkin RM; Samuelson JS; Gotlin LP Dev Biol Stand; 1985; 61():297-307. PubMed ID: 2872117 [TBL] [Abstract][Full Text] [Related]
51. Evaluation of the pertussis components of diphtheria-tetanus-pertussis vaccine. Murphy MD; Rasnack J; Dickson HD; Dietch M; Brunell PA Pediatrics; 1983 Feb; 71(2):200-5. PubMed ID: 6296755 [TBL] [Abstract][Full Text] [Related]
52. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea. Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828 [TBL] [Abstract][Full Text] [Related]
53. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Tapiainen T; Cherry JD; Heininger U Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771 [TBL] [Abstract][Full Text] [Related]
54. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Englund JA; Anderson EL; Reed GF; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Rennels MB; Deforest A; Meade BD Pediatrics; 1995 Sep; 96(3 Pt 2):580-4. PubMed ID: 7659480 [TBL] [Abstract][Full Text] [Related]
55. New combination vaccines still need a boost. Pollard AJ Arch Dis Child; 2007 Jan; 92(1):1-2. PubMed ID: 17185438 [TBL] [Abstract][Full Text] [Related]
56. A consideration of control requirements for acellular pertussis vaccines. Corbel MJ; Xing DK Dev Biol Stand; 1997; 89():343-7. PubMed ID: 9272369 [No Abstract] [Full Text] [Related]
58. Pertussis immunization of infants using a new combined DTP-polio vaccine. Drucker J; Schatzmayr H; Grenier B; Ajjan N; Peyron L; Roumiantzeff M Dev Biol Stand; 1985; 61():309-13. PubMed ID: 2872119 [TBL] [Abstract][Full Text] [Related]
59. Response of infants to Haemophilus influenzae type b polysaccharide and diphtheria-tetanus-pertussis vaccines in combination. Lepow ML; Peter G; Glode MP; Daum RS; Calnen G; Knight KM; Mayer D; Kuo JS; Lui NS J Infect Dis; 1984 Jun; 149(6):950-5. PubMed ID: 6376656 [TBL] [Abstract][Full Text] [Related]
60. Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines. Gupta RK; Anderson R; Cecchini D; Rost B; Griffin P; Benscoter K; Xu J; Montanez-Ortiz L; Siber GR Dev Biol Stand; 1996; 86():283-96. PubMed ID: 8785957 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]